A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.

Filip JankuMilind M JavleShiraj SenShubham PantLindsay G BramwellVivek SubbiahTracey WayDavid S WagesCatherine A WheelerTakeaki SuzukiKazunori SaekiRuth Ann SubachTimothy MaddenGary MaierMary J JohansenKin CheungGerald S Falchook

Published in: Cancer (2023)

FF-10502-01 was well tolerated with manageable side effects and limited hematologic toxicity. Durable PRs and disease stabilizations were observed in heavily pretreated biliary tract patients who had received prior gemcitabine. FF-10502-01 is distinct from gemcitabine and may represent an effective therapy.

Keyphrases

locally advanced
oxidative stress
stem cells
radiation therapy
mesenchymal stem cells
combination therapy
rectal cancer
smoking cessation